Loading clinical trials...
Loading clinical trials...
This study will evaluate the tolerability and safety of valsartan in patients with stable, chronic heart failure (NYHA Class ll-lll). The 12-week double blind study has a 2-week (maximum) screening, a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT06148935 · Chronic Heart Failure With Reduced Ejection Fraction
NCT06659393 · Pediatric Chronic Heart Failure
NCT04471129 · Chronic Heart Failure
NCT07434193 · Chronic Heart Failure
NCT07379840 · Chronic Heart Failure
Novartis Pharmaceuticals
East Hanover, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions